These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17369197)

  • 21. Evaluation of the Vitotox and RadarScreen assays for the rapid assessment of genotoxicity in the early research phase of drug development.
    Westerink WM; Stevenson JC; Lauwers A; Griffioen G; Horbach GJ; Schoonen WG
    Mutat Res; 2009 May; 676(1-2):113-30. PubMed ID: 19393335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites.
    Galloway SM
    Environ Mol Mutagen; 2017 Jun; 58(5):296-324. PubMed ID: 28299826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity.
    Ellinger-Ziegelbauer H; Aubrecht J; Kleinjans JC; Ahr HJ
    Toxicol Lett; 2009 Apr; 186(1):36-44. PubMed ID: 18822359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Report of the IWGT working group on strategies and interpretation of regulatory in vivo tests I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards.
    Tweats DJ; Blakey D; Heflich RH; Jacobs A; Jacobsen SD; Morita T; Nohmi T; O'Donovan MR; Sasaki YF; Sofuni T; Tice R;
    Mutat Res; 2007 Feb; 627(1):78-91. PubMed ID: 17116417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of genotoxicity test procedures with Episkin, a reconstructed human skin model: towards new tools for in vitro risk assessment of dermally applied compounds?
    Flamand N; Marrot L; Belaidi JP; Bourouf L; Dourille E; Feltes M; Meunier JR
    Mutat Res; 2006 Jul; 606(1-2):39-51. PubMed ID: 16675293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules.
    Snyder RD; Pearl GS; Mandakas G; Choy WN; Goodsaid F; Rosenblum IY
    Environ Mol Mutagen; 2004; 43(3):143-58. PubMed ID: 15065202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment.
    Trosko JE; Chang CC
    Toxicology; 2010 Mar; 270(1):18-34. PubMed ID: 19948204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotoxicity testing: current practices and strategies used by the pharmaceutical industry.
    Purves D; Harvey C; Tweats D; Lumley CE
    Mutagenesis; 1995 Jul; 10(4):297-312. PubMed ID: 7476265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard.
    Silva Lima B; Van der Laan JW
    Regul Toxicol Pharmacol; 2000 Oct; 32(2):135-43. PubMed ID: 11067770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic toxicity assessment: employing the best science for human safety evaluation. Part II: Performances of the in vitro micronucleus test compared to the mouse lymphoma assay and the in vitro chromosome aberration assay.
    Lorge E; Lambert C; Gervais V; Becourt-Lhote N; Delongeas JL; Claude N
    Toxicol Sci; 2007 Apr; 96(2):214-7. PubMed ID: 17192442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
    Bercu JP; Hoffman WP; Lee C; Ness DK
    Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations on photochemical genotoxicity. II: report of the 2009 International Workshop on Genotoxicity Testing Working Group.
    Lynch AM; Guzzie PJ; Bauer D; Gocke E; Itoh S; Jacobs A; Krul CA; Schepky A; Tanaka N; Kasper P
    Mutat Res; 2011 Aug; 723(2):91-100. PubMed ID: 21296679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals.
    Van Deun K; Van Cauteren H; Vandenberghe J; Canning M; Vanparys P; Coussement W
    Adverse Drug React Toxicol Rev; 1997 Nov; 16(4):215-33. PubMed ID: 9608857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The in vivo comet assay: use and status in genotoxicity testing.
    Brendler-Schwaab S; Hartmann A; Pfuhler S; Speit G
    Mutagenesis; 2005 Jul; 20(4):245-54. PubMed ID: 15899933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of genotoxic impurities in pharmaceutical development.
    Bercu JP; Dobo KL; Gocke E; McGovern TJ
    Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A.
    Wu KM; Dou J; Ghantous H; Chen S; Bigger A; Birnkrant D
    Regul Toxicol Pharmacol; 2010 Feb; 56(1):1-3. PubMed ID: 19782117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance of ICH--toxicokinetics guidance and its practice--a useful approach for safety drug development].
    Tsuda M; Ohno Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1997; (115):1-14. PubMed ID: 9641814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.